Systemic sclerosis & Raynaud's
Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis
Authors' conclusion
Serum CCL24 is a biomarker of disease severity across fibrotic and vascular disease manifestations.
Study context
- Population
- Consecutively enrolled patients with systemic sclerosis (SSc) in a real-life observational cohort (median disease duration 6 years, IQR 3–14)25.3% high CCL24
- Participants
- 213 participants
- Exposure
- High vs non-high serum CCL24
- Outcome
- Clinical features by serum CCL24 level
Methodological detailsobservational, consecutively enrolled, matched healthy control cohort for CCL24 cutoff
- Observational
- Consecutively enrolled
- Matched healthy control cohort for CCL24 cutoff
Main finding
As reported in the abstract
- High-CCL24 patients more frequently male, anti-scl-70 positive, with interstitial lung disease (ILD) and synovitis
- P < 0.05 for all
- High-CCL24 patients had lower DLCO and higher prevalence of digital ulcers, telangiectasias and calcinosis
- P < 0.05 for all
Observational data: associations, not effects.
Further findings
Longitudinal lung function decline and disease-related mortality
- High CCL24 associated with greater lung function decline and higher disease-related mortality
Original publication
Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis. Arthritis Care Res (Hoboken). Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →